Last checked at 23 Jun 2022 15:59
AstraZeneca's Wilson disease treatment shows promise in phase 3 trials
(Alliance News) - AstraZeneca PLC on Thursday reported strong results from phase III clinical trials for ALXN1840.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades16,417
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,050.00
Bid:
12,038.00
Ask:
12,040.00
Change:
-106.00 (-0.87%)
Spread:
2.00 (0.017%)
Open:
12,092.00
High:
12,178.00
Low:
12,010.00
Prev. Close:
12,156.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.22 Jun 2022 10:06
Citi reiterates 'buy' on AstraZeneca on the back of trial results for Enhertu against breast cancer
(Sharecast News) - Analysts at Citi reiterated their 'buy' recommendation for shares of AstraZeneca following the release of the results of the DESTINY-Breast 04 clinical trial using its Enhertu treatment against metastatic breast cancer.
Read more22 Jun 2022 08:00
19 vaccine scheme for world's poorest pushes for delivery slowdown
LONDON, June 22 (Reuters) - Leaders of the global scheme aiming to get COVID-19 vaccines to the world's poorest are pushing manufacturers including Pfizer and Moderna to cut or slow deliveries of about half a billion shots so doses are not wasted.
Read more21 Jun 2022 22:01
Merck & Co, Astra drug improves survival in prostate cancer sufferers
(Alliance News) - Merck & Co Inc on Tuesday said its Lynparza drug, developed alongside AstraZeneca PLC, improved survival rates for some sufferers of prostate cancer.
Read more21 Jun 2022 08:32
AstraZeneca's polyneuropathy candidate Eplontersen sees positive data
(Alliance News) - AstraZeneca PLC on Tuesday said eplontersen, its candidate for a form of hereditary polyneuropathy, demonstrated significant positive results in a phase 3 trial interim analysis.
Read more21 Jun 2022 08:13
AstraZeneca receives 'positive' results from Phase III trial on eplontersen
(Sharecast News) - Drugmaker AstraZeneca has received positive high-level results from an interim analysis of its NEURO-TTRansform Phase III trial on eplontersen, the group's hereditary transthyretin-mediated amyloid polyneuropathy drug candidate.
Read more17 Jun 2022 21:34
Early Omicron infection unlikely to protect against current variants
NEW YORK, June 17 (Reuters) - People infected with the earliest version of the Omicron variant of the coronavirus, first identified in South Africa in November, may be vulnerable to reinfection with later versions of Omicron even if they have been vaccinated and boosted, new findings suggest.
Read more17 Jun 2022 21:26
Early Omicron infection unlikely to protect against current variants
NEW YORK, June 17 (Reuters) - People infected with the earliest version of the Omicron variant of the coronavirus, first identified in South Africa in November, may be vulnerable to reinfection with later versions of Omicron even if they have been vaccinated and boosted, new findings suggest.
Read more14 Jun 2022 16:49
EU states step up pressure on Pfizer to cut unneeded COVID vaccine supplies
BRUSSELS, June 14 (Reuters) - European Union governments are intensifying pressure on Pfizer and other COVID-19 vaccine makers to renegotiate contracts, warning millions of shots that are no longer needed could go to waste, according to EU officials and a document.
Read more14 Jun 2022 12:02
LONDON MARKET MIDDAY: Rebound stumbles as US Fed hike jitters grow
(Alliance News) - Tuesday's dead cat bounce didn't live past the morning in Europe, with the FTSE 100 back in the red at midday as investors fret over an upcoming US interest rate decision.
Read more14 Jun 2022 09:33
LONDON BROKER RATINGS: Berenberg and HSBC upgrade Wizz Air
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more14 Jun 2022 08:17
LONDON BRIEFING: BoE dilemma as basic UK pay falls 2.2% in real terms
(Alliance News) - Average pay in the UK is failing to keep up with rampant inflation, though the country's jobless rate remains at nearly a 50-year low, posing a conundrum for the Bank of England when it meets this week.
Read more13 Jun 2022 15:17
Valneva shares plunge as European COVID vaccine deal flounders
PARIS/LONDON, June 13 (Reuters) - Valneva shed around a quarter of its market value on Monday after the French drugmaker warned that the future of its COVID-19 vaccine was in jeopardy.
Read more13 Jun 2022 13:52
Daiichi Sankyo doses first person in breast cancer treatment trial
(Alliance News) - Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in patients with breast cancer.
Read more10 Jun 2022 09:33
GSK closer to cracking elusive vaccine for common respiratory virus
LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.
Read more